_immunomodulators-part-2-immunostimulants-preview-1.jpg "Immunomodulators Part 2: Immunostimulants from immunomodulatory therapy Video Screenshot Preview 1")
Gallery_immunomodulators-part-2-immunostimulants-preview-3.jpg "Immunomodulators Part 2: Immunostimulants from immunomodulatory therapy Video Screenshot Preview 3")
Gallery_immunomodulators-part-2-immunostimulants-preview-hqdefault.jpg "Immunomodulators Part 2: Immunostimulants from immunomodulatory therapy Video Screenshot Preview hqdefault")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Jump To Video Parts
⏲ Duration: 5 minutes 27 seconds
👁 View: 12K times
Play Audio:👁 View: 12K times
Description:
Professor Dave Explains
Professor Dave Explains
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_the-imsavar-project-making-immunomodulatory-therapies-safer.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
_immunomodulators-part-2-immunostimulants.webp "Professor Dave Explains")
_what-should-you-know-about-myeloma-treatment-options.webp "Dr. Peter Forsberg outlines options in the myeloma treatment toolkit, including targeted therapies, chemotherapy, immunotherapy, and combination approaches —and explains how the recovery process from stem cell transplant has improved.nnDr. Peter Forsberg is assistant professor of medicine at the University of Colorado School of Medicine and is a specialist in multiple myeloma. More about Dr. Forsberg here: https://www.cudoctors.com/Find_A_Doctor/Profile/24672.")
_pharmacology-immune-system-drugs-full-video-nursing-rn-pn-nclex.webp "Simple Nursing")
_at-100-recombinant-human-surfactant-protein-d.webp "AT-100 is a recombinant form of human surfactant protein-D (rhSP-D). SP-D, absent from current therapies, is a normal protein component of lung surfactant that performs three critical roles in maintaining healthy lung function.nn1. Surfactant Homeostasisn2. Immunomodulatoryn3. Anti-inflammatorynnAT-100 augments current therapy:n- Current therapy is commercial lung surfactant—40% of very low birth weight babies don’t respond to this therapyn- AT-100 adds back the missing surfactant protein-Dn")
_immunomodulatory-therapy-for-fl-the-r-regimen.webp "OncLiveTV")
_current-and-future-directions-for-novel-therapy-for-multiple-myeloma-paul-g-richardson-md.webp "Dana-Farber Cancer Institute")
⏲ 37 minutes 46 seconds 👁 930
_myeloma-treatment-decisions-whats-right-for-you.webp "When choosing an myeloma treatment, what should be considered? Dr. Peter Forsberg, a myeloma specialist, reviews key decision-making factors, treatment options for myeloma, including combination approaches, and shares advice on advocating for yourself. nnDr. Peter Forsberg is assistant professor of medicine at the University of Colorado School of Medicine and is a specialist in multiple myeloma. More about Dr. Forsberg here: https://www.cudoctors.com/Find_A_Doctor/Profile/24672.")
_the-imsavar-project-making-immunomodulatory-therapies-safer.jpg)
_immunomodulators-part-2-immunostimulants.jpg)
_what-should-you-know-about-myeloma-treatment-options.jpg)
_pharmacology-immune-system-drugs-full-video-nursing-rn-pn-nclex.jpg)
_at-100-recombinant-human-surfactant-protein-d.jpg)
_immunomodulatory-therapy-for-fl-the-r-regimen.jpg)
_current-and-future-directions-for-novel-therapy-for-multiple-myeloma-paul-g-richardson-md.jpg)
_myeloma-treatment-decisions-whats-right-for-you.jpg)
![[+]](/images/menu.gif){kind=small}